Cardiovascular drug developer ABIONYX Pharma's H1 revenue falls

Abionyx Pharma SA

27/08/2026 18:17

Overview
France biopharma firm's preliminary H1 2026 revenue was €1.9 mln, all from IRIS Pharma CRO
Company reported no revenue from core biotech activity, providing bioproduct free under Compassionate Use
Cash and cash equivalents at June 30, 2026 were €26.9 mln after recent financing

Outlook
Company expects IRIS Pharma revenue for 2026 to remain broadly stable versus 2025
ABIONYX Pharma says financial visibility extends through end of 2028

Result Drivers
NO CORE BIOTECH REVENUE - Co reported no revenue from core biotech activity, as it continued to provide its bioproduct free under Compassionate Use Authorization
CRO REVENUE - All H1 2026 revenue came from IRIS Pharma's contract research organization activities in ophthalmology

Company press release: ID:nBw1hD2Rfa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
EUR 1.90 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Abionyx Pharma SA is €10.42, about 420.8% above its August 27 closing price of €2.00

Reuters Recommended Reads
Aug 27 - Germany's BRAIN Biotech 9M revenue falls 10.5% on core unit weakness
Aug 25 - Canada's LSL Pharma Q2 revenue surges on acquisition boost, eye-drop launches
Aug 27 - Denmark's Curasight Q2 loss narrows

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)